Odonate Therapeutics Inc (NASDAQ:ODT) Receives Average Recommendation of “Strong Buy” from Brokerages

Shares of Odonate Therapeutics Inc (NASDAQ:ODT) have been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Analysts have set a twelve-month consensus target price of $45.00 for the company and are anticipating that the company will post ($1.03) EPS for the current quarter, according to Zacks. Zacks has also assigned Odonate Therapeutics an industry rank of 97 out of 256 based on the ratings given to related companies.

A number of equities research analysts have recently commented on the stock. Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. ValuEngine cut shares of Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 18th. Finally, Cowen reaffirmed a “buy” rating on shares of Odonate Therapeutics in a report on Monday, June 3rd.

ODT traded up $2.08 on Monday, reaching $38.02. The company had a trading volume of 172,746 shares, compared to its average volume of 158,045. Odonate Therapeutics has a 1 year low of $11.54 and a 1 year high of $38.80. The company has a market cap of $1.16 billion, a PE ratio of -10.45 and a beta of 1.68. The stock’s 50-day simple moving average is $32.15.

Odonate Therapeutics (NASDAQ:ODT) last announced its quarterly earnings results on Wednesday, July 24th. The company reported ($1.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.09. As a group, analysts forecast that Odonate Therapeutics will post -4.59 earnings per share for the current year.

In other news, CEO Kevin C. Tang purchased 93,692 shares of the company’s stock in a transaction dated Wednesday, June 5th. The shares were acquired at an average cost of $24.92 per share, for a total transaction of $2,334,804.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin C. Tang purchased 50,000 shares of the company’s stock in a transaction dated Tuesday, June 18th. The shares were purchased at an average price of $26.15 per share, for a total transaction of $1,307,500.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 1,393,077 shares of company stock worth $36,230,094. Company insiders own 59.30% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Arbitrage SA grew its position in Odonate Therapeutics by 1,187.5% during the first quarter. BNP Paribas Arbitrage SA now owns 1,442 shares of the company’s stock worth $32,000 after buying an additional 1,330 shares during the period. Strs Ohio grew its position in Odonate Therapeutics by 678.9% during the second quarter. Strs Ohio now owns 14,800 shares of the company’s stock worth $543,000 after buying an additional 12,900 shares during the period. California Public Employees Retirement System acquired a new position in Odonate Therapeutics during the first quarter worth about $1,548,000. Northern Trust Corp grew its position in shares of Odonate Therapeutics by 11.1% in the fourth quarter. Northern Trust Corp now owns 91,550 shares of the company’s stock valued at $1,289,000 after purchasing an additional 9,125 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Odonate Therapeutics by 29.1% in the fourth quarter. Geode Capital Management LLC now owns 93,842 shares of the company’s stock valued at $1,321,000 after purchasing an additional 21,168 shares during the last quarter. Institutional investors own 91.48% of the company’s stock.

About Odonate Therapeutics

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Featured Article: When is a capital gain realized?

Get a free copy of the Zacks research report on Odonate Therapeutics (ODT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.